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Background: Triple negative breast cancer (TNBC) has higher rates of recurrence and distant metastasis, and poorer
outcome as compared to non-TNBC. Aberrant activation of WNT signaling has been detected in TNBC, which might
be important for triggering oncogenic conversion of breast epithelial cell. Therefore, we directed our focus on
identifying the WNT ligand and its underlying mechanism in TNBC cells.
Methods: We performed large-scale analysis of public microarray data to screen the WNT ligands and the clinical
significance of the responsible ligand in TNBC. WNT5B was identified and its overexpression in TNBC was confirmed
by immunohistochemistry staining, Western blot and ELISA. ShRNA was used to knockdown WNT5B expression
(shWNT5B). Cellular functional alteration with shWNT5B treatment was determined by using wound healing assay,
mammosphere assay; while cell cycle and apoptosis were examined by flowcytometry. Mitochondrial morphology
was photographed by electron microscope. Biological change of mitochondria was detected by RT-PCR and oxygen
consumption assay. Activation of WNT pathway and its downstream targets were evaluated by liciferase assay,
immunohistochemistry staining and immunoblot analysis. Statistical methods used in the experiments besides
microarray analysis was two-tailed t-test.
Results: WNT5B was elevated both in the tumor and the patients’ serum. Suppression of WNT5B remarkably impaired
cell growth, migration and mammosphere formation. Additionally, G0/G1 cell cycle arrest and caspase-independent
apoptosis was observed. Study of the possible mechanism indicated that these effects occurred through suppression of
mitochondrial biogenesis, as evidenced by reduced mitochondrial DNA (MtDNA) and compromised oxidative
phosphorylation (OXPHOS). In Vivo and in vitro data uncovered that WNT5B modulated mitochondrial physiology
was mediated by MCL1, which was regulated by WNT/β-catenin responsive gene, Myc. Clinic data analysis revealed that
both WNT5B and MCL1 are associated with enhanced metastasis and decreased disease-free survival.
Conclusions: All our findings suggested that WNT5B/MCL1 cascade is critical for TNBC and understanding its regulatory
apparatus provided valuable insight into the pathogenesis of the tumor development and the guidance for targeting
therapeutics.
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Triple negative breast cancer (TNBC) is an aggressive form
of breast cancer characterized by the lack of estrogen,
progesterone receptors (ER, PR) and lack of amplification
of human epidermal growth factor receptor 2 (HER2)
[1]. With the major contribution of adjuvant targeting* Correspondence: yyen@coh.org
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unless otherwise stated.therapies, the outcome of breast cancer has been improved
dramatically; yet the prognosis of TBNC remains quite
poor among the breast cancer subtypes [2-4]. It is largely
due to the heterogeneous nature of TNBC and unrespon-
siveness to the clinic available targeting therapies [5-7].
Many attempts to identify the key oncogenic pathways at
the molecular level have been carried out. Aberration of
WNT signal is widely recognized as one of the potential
pathway that contributes to TNBC tumorigenicity [8-11].d. This is an Open Access article distributed under the terms of the Creative
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late various processes that are crucial for development
and growth, cell fate decision, cell proliferation/differ-
entiation and stem cell self-renewal [12-14]. Activation
of WNT signaling cascade is initiated through the
binding of WNT with its receptor/co-receptor. WNT/
β-catenin is the first indentified WNT pathway that
is aberrantly activated in human colorectal cancer
[15,16]. Since then, the complicated signals triggered
by WNT, but following distinct pathways have been
detected. The complexity of these signals is partially
attributed to the multiple members of WNT family
and various subtypes of receptor/co-receptor [17]. The
cellular response to a given WNT ligand is ultimately
context-specific and the dynamic interactions deter-
mine the net outcome [18]. Emerging evidence has been
demonstrated that WNT signaling is actively involving in
many cellular biologic processes via integrating WNT signal
to other major cellular pathways, including mitochondrial
homeostatic pathway [19].
Mitochondria engage in various biochemical activities
and are the major organelle to generate ATP. In addition
to their function as the power plants, they are involving
in many other vital cellular processes, such as cell
apoptosis, cell cycle control, cell differentiation and
cell proliferation [20,21]. The functional and active
mitochondria status is actually essential for cancer cell
physiology. Despite frequent mitochondrial gene muta-
tions are detected in human tumor; they don’t turn off
the mitochondrial energy metabolism at all. Addition-
ally, they regulate the mitochondrial bioenergetic and
biogenetic state [22]. However, how cancer cells modu-
late mitochondrial status to meet their biological need
is under current study. In the current project, we
present evidence to demonstrate that MCL1 is a key
regulator for TNBC cell survival mediated by control-
ling mitochondrial biogenesis.
Methods
Patients, tissues and serum
All tumor tissues and serum were collected under the
Institutional Review Board (IRB)-approved protocols
at City of Hope National Medical Center (COH) or
Zhejiang University respectively. The patients were
given informed consent. One hundred and forty-two
breast tumor tissues, including 21 TNBC and 121
Non-TNBC tissues were collected for immunohisto-
chemistry staining. We also collected 30 sera from
TNBC and Non-TNBC patients respectively with the
assistance from the COH Translational Research La-
boratory Core for ELISA assay. Immunohistochemical
staining and FISH confirmed that ER/PR/HER2 were
negatively expressed, as assessed by pathologists in the
Department of Pathology of COH.Microarray analysis
For differential expression analysis, differential expres-
sion P-values were determined via t-test in R [23].
Significant results are expected to show P-value < 0.05.
Differential expression between TNBC and non-TNBC
was determined using data from 3 cohorts (Chin et al.
[24], expO (GSE2109), and TCGA [25]. Differential ex-
pression between patients that did or did not develop
metastatic tumors was determined using 2 cohorts
(expO (GSE2109), TCGA [25] for WNT5B and 1 co-
hort (Desmedt et al.) for MCL1. For survival analysis,
differences in survival between “high” and “low” ex-
pression groups were visualized in Kaplan-Meier plots
and compared using Cox regression analysis, with
P-values calculated via log-rank test, using the ‘sur-
vival’ package in R (A Language and Environment for
Statistical Computing). The disease-free survival of
WNT5B was quantified independently for 2 cohorts
(Desmedt et al. and Wang et al. [26,27]) respectively.
And then meta-analysis was conducted by utilizing the
same WNT5B probe (so that the signals would be
comparable) for an 80 month observation period. The
disease-free survival of MCL1 was analyzed by the
same method using the cohort of Desmedt et al.
RT-PCR, RT-qPCR and qPCR
Total RNA extraction from MDA-MB-231 was carried
out using the RNeasy Mini Kit (Qiagen). For cDNA syn-
thesis, total RNA (1 μg) was transcribed using random
hexamers (Invitrogen, Carlsbad, CA), and SuperScript III
reverse transcriptase (Invitrogen) following the manufac-
turer’s protocol. For quantification of OXPHOS-related
genes, the cDNA amplication program included a de-
nature at 95°C for 3 min, followed by 40 cycles of 95°C
for 10 s; 58°C for 30 s. For MtDNA detection, total cel-
lular DNA was isolated with DNAeasy Blood and Tissue
Kit (Qiagen). Mitochondrial DNA content was deter-
mined by qPCR by using comparing the mitochondrially
encoded Cox2 gene to an intron of the nuclear-encoded
β-globin (HBB) gene. All qPCR was performed using an
iQ5 iCycler (Bio-Rad) according to the manufacturer’s
instructions. Data were analyzed using Bio-Rad iQ5
Optical System Software v2.0. All products yielded a sin-
gle band with the predicted size. All primers are listed in
Additional file 1: Table S1 and all products yielded a
single band with the predicted size.
Western blot analysis
Cell protein was extracted from cells using RIPA buffer
(Cell Signaling, Danvers, MA) with phosphatase inhibitor
(Roche, Indianapolis, IN). Equal amount of protein was
loaded and separated by SDS-PAGE. After the protein was
transferred onto a membrane, the blot was blocked with
5% non-fat milk in TBS and probed overnight at 4°C using
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Louis, MO), Cyclin E (M20), TOM20 (F-10), Myc
(9E10), AIF (E-1), MCL1 (S-19) (Santa Cruz Biotechnology,
Santa Cruz, CA), Caspsae-3, Caspase-8,PGC-α, Cyclin
D1 (Cell Signaling, Danvers, MA) and β-actin (Bio-Rad,
Hercules, CA). Appropriate antibodies were used for
secondary antibody reaction. Signal was detected by the
ECL Plus Western Blot Detecting System (GE Healthcare,
Piscataway, NJ).Cell culture and growth assays
The triple negative cell lines MDA-MB-231was pur-
chased from ATCC and cultured in the recommended
media. Specific lentivirus shRNA (Sigma-Aldrich) was used
to disrupt the expression of WNT5B while shRNA target-
ing non-mammalian sequence (Sigma-Aldrich) served as
control. WNT5B expression was determined by immu-
noblot analysis. MDA-MB-231 cells that expressed
WNT5B or control shRNA (shWNT5B or shCtl cells)
were cultured in growth medium to observe cell
growth. Cells (3 × 104/ml) were seeded into 24-well
plates, and cell number was counted every day for
five days using a Cellometer Auto T4 (Nexcelom
Bioscience, Lawrence, MA). Independent experiments
were performed in triplicate.Cell morphology, invasion
Cells were infected with shCtl or shWNT5B lentivirus
and the morphology was observed and photographed
after WNT5B expression was inhibited. Cell mobility
was determined by a wound closure assay. Cells were
placed onto 6-well plates at 80% confluence and cultured
in serum-depleted media for 40 h. A wound was made
by scraping the monolayer cells with a plastic pipette tip
and fresh serum-free medium was replenished. Images
of wound closure were photographed at 0, 16, 24 and
40 h post-scraping.Flowcytometry
Cells were trypsinized, resuspend in fresh medium followed
by flowcytometry analysis. For cell cycle assay, cells were
fixed with 70% ethanol and incubated on ice for 30
min. The cells were then suspended in PBS and treated
with RNase A (final concentration 100ug/ml) at 37°C for
30 min. After removing RNase A, the cells were stained
with propidium iodide (PI) at 5ug/ml for 10 min and the
cell cycle was determined by flowcytometry analysis. For
apoptosis assay, FITC Annexin V Apoptosis Detection Kit
was used for staining the cells following product’s manual
(BD bioscience). All flowcytometry data were analyzed
using Summit v4.3 software.Immunohistochemical (IHC) staining
All the formalin-fixed paraffin-embedded (FFPE) slides
were prepared and stained by the Pathology Core Facility
at COH using a standard protocol. Antibodies used in
this study were: rabbit polyclonal antibodyWNT5B
(SAB2900204) (1:20 dilution, Sigma-Aldrich), mouse
monoclonal antibody Myc (SC-40) (1:75 dilution, Santa
Cruz Biotechnology) and rabbit monoclonal antibody
MCL1 (ab32087) (1: 100 dilution, Abcam). All anti-
bodies were titrated with negative and positive controls
to obtain optimal staining.
Electon microscope (EM)
The cells infected with shWNT5B or shCtl were col-
lected in 3 days. The electron microscope was done in
the core facility at COH following their standard proto-
col. It has been described in detail elsewhere [28]. The
stained sections were subjected to Electron microscopy,
which was done on an FEI Tecnai 12 transmission elec-
tron microscope equipped with a Gatan Ultrascan 2 K
CCD camera.
Oxygen consumption rate (OCR) and ATP measurement
The XF24 flux analyzer (Seahorse Bioscience) was used
to measure OCR in 24-well microplates. Six thousand
cells transduced with shCtl and 12000 cells infected with
shWNT5B lenti-virus were seeded onto 24-well plates
and incubated 3 days. The measurement, recording pro-
cedure and data analysis were described previously [29].
For cellular ATP measurement, we used ENLITEN ATP
Assay System Bioluminescence Detection Kit (Promega
Madison, WI). Briefly, the adherent cells in 6-well plate
were collected by 2 mM EDTA in PBS on ice, TCA was
add at final concentration of 1% and vortex vigorously for
10 sec. It was further diluted to 0.1% TCA by Tris-Acetate
(pH = 7.75). The standard as well as the samples were seri-
ally diluted by dilution buffer (0.1% TCA/0.08 × PBS/0.9 ×
Tris-Acetate) and subjected to luminescence measurement.
ELISA assay
To measure soluble WNT5B in patients’ serum, we used
WNT5B ELISA Kit (USCN Life Science Inc.). The man-
ufacture’s protocol was totally followed for preparing
samples and all the reactions. The plate was read by
SpectramaxPlus (Molecular Devices).
Luciferase assay
ShWNT5B- or shCtl- virus transduced MDA-MB-231
cells were distributed into 12-well plates the day before
transfection. Cells at 80% confluence were co-transfected
with TCF-driven Topflash reporter plasmid (Millipore)
(1 μg) and control Renilla luciferease (20 ng) using 2.5 μl of
Lipofectamine 2000 (Invitrogen). Cells were lysed in 1X
passive lysis buffer in 48 h and the supernatant was
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mega, Madison, WI). For each sample, firefly luciferase
activity was normalized with an internal control, Renilla
luciferase activity.
Results
WNT5B was upregulated in triple negative breast cancer
We have previously performed microarray on 19 breast
tumors, including 4 TNBC and non-TNBC tumors. We
have reported the significant activation of WNT signal-
ing in TNBC. To look for the ligand that might be im-
portant for TNBC tumorigenesis, we performed large
scale public microarray data analysis instead of using
our limited samples to achieve meaningful significance.
As summarized in Additional file 1: Table S2; Title:
Cohorts used in this study, cDNA microarry or RNA
sequence data from 5 cohorts were collected [24-27] and
used for comprehensive analysis of differential gene ex-
pression, metastasis and disease-free survival. The three












































Figure 1 WNT5B was upregulated in TNBC. (A) Differential expression o
TCGA (n = 779), P = 0.0115. (B) Immunohistochemistry (IHC) staining of WN
staining of WNT5B in TNBC and non-TNBC tissues, positive staining rate wa
non-TNBC sera. Each dot represented the mean values 3 independent expe
lines. *P < 0.05, which was considered statistically significant.determine the differential expression between TNBC and
Non-TNBC (Additional file 1: Table S2; Title: Cohorts used
in this study). WNT5B mRNA was identified as one of the
overexpressed gene in TNBC among 779 breast cancer tis-
sues in TCGA data analysis (Figure 1a, Additional file 1:
Table S1). The similar finding was observed in the analysis
of other two analyses, which included 130 and 354 breast
cancer tumors respectively (Additional file 1: Table S2;
Title: Cohorts used in this study and Additional file 1:
Figure S1). We validated the microarray results by
immunohistochemistry (IHC) staining of WNT5B in
breast cancer tissue array samples (Figure 1b). WNT5B
was detected in 14 of 21 TNBC, while only 48 of 121
Non-TNBC tissues expressed WNT5B. Statistic ana-
lysis indicated that there was significant difference
between TNBC and Non-TNBC (Figure 1c). Through
autocrine or paracrine, WNT5B is secreted into the
serum to function by binding to the cell surface recep-
tor and co-receptor. Therefore, we randomly picked up






f WNT5B in TNBC and non-TNBC tissues was analyzed using cohorts of
T5B in 21 TNBC and 121 non-TNBC tissues. (C) Statistical analysis of IHC
s plotted, P = 0.0379. (D) ELISA analysis of WNT5B in 30 TNBC and 30
riments. P = 0.0491. (E) Western blot of WNT5B in breast cancer cell
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The average WNT5B in patients’ plasma was 115.01 ng/ml
in TNBC; and 84.86 ng/ml in Non-TNBC. With approxi-
mately 30 ng/ml greater in TNBC than in Non-TNBC, and
is a statically significant difference (Figure 1d). We further
screened the WNT5B expression in breast cancer cell
lines. RT-PCR results revealed that WNT5B predominantly
expressed in TNBC-derived cell lines, HCC1937, MDA-
MB-231 and BT-20; but not other Non-TNBC cell lines
(Additional file 1: Figure S2) and this was confirmed with
immunoblot analysis (Figure 1e). This finding suggested
that WNT5B may play a role in TNBC.
ShWNT5B led to impairment of cancerous features in
TNBC cells
To investigate the role of WNT5B plays in TNBC, we
knockdown WNT5B by short hairpin RNA (shWNT5B)
in TNBC-derived cell line MDA-MB-231 cells (MDA-
MB-231/shWNT5B). The short hairpin RNA targeting
non-mammalian sequence was served as control (shCtl).
After 3 days expression of shWNT5B, MDA-MB-231
cell altered its morphology from spindle to round shape
with poor attachment (Figure 2a). Flowcytometry was
performed to determine the cell size. Decreased cell
size was observed in MDA-MB-231/shWNT5B cells
(Additional file 1: Figure S3A). We also measured the





Figure 2 Knockdown of WNT5B led to decreased functional change in
was expressed. (B) Cell growth curve with WNT5B knockdown compared t
(n = 3). Cells were observed for 5 days. ***P < 0.001 (C) ShWNT5B inhibited
24 and 40 h after wounding was photographed in MDA-MB-231 cells trans
formation in MDA-MB-231 cells. A representative mammary sphere image w
enumerated. Scale bar: 20 um; the graph represents an average of 3 indep231 cells. It significantly decelerated in MDA-MB-231/
shWNT5B cells as compared to shCtl-transduced cells
or non-infected MDA-MB-231 cells (Figure 2b). The cell
mobility was then examined by a wound healing assay.
MDA-MB-231 cells infected with shCtl moved to the
wound area within 16 h and completely closed the
wound within 40 h; whereas in MDA-MB-231/WNT5B
cells, the wound remained open, even after 40 h (Figure 2c).
In proliferation assay, the cells transduced with shWNT5B
demonstrated decreased proliferation comparing to control
cells (Additional file 1: Figure S3B). These results indicate
that WNT5B is a key factor to control cancer cell biology,
especially in cell growth, motility, and tumorigenicity.
ShWNT5B induced cell cycle arrest and caspase-
independent cell death
Given the cells growth worsened dramatically after
WNT5B was inhibited, we assessed whether cell cycle
transition was blocked. As it was shown in Figure 3a,
cells with WNT5B knockdown underwent greatly in-
creased G0/G1 cell cycle arrest. Cyclin E is an essential
protein for the G1- to- S phase transition and it is
regulated by Cyclin D1. To evaluate whether G0/G1
cell cycle arrest is due to the deregulation of Cyclin E
and Cyclin D1, immunoblot was performed to examine
Cyclin E and Cyclin D1 expression. As a result, with






















MDA-MB-231 cells. (A) Morphology alteration 3 days after shWNT5B
o control cells. Each point represents cell number as the mean ± SD
wound healing in MDA-MB-231 cells. Wound healing status at 0, 16,
duced with shWNT5B or shCtl. ShWNT5B attenuated mammary sphere
as taken (Left panel), and the sphere size greater than 50 um was
endent experiments. P = 0.0094, **P < 0.01 (Right panel).
A B
C D
Figure 3 ShWNT5B induced cell cycle arrest and caspase-independent apoptosis in MDA-MB-231 cells. (A) Cells arrested in G0/G1 phase.
Cells were infected with shCtl or shWNT5B, and the cell cycle was examined 3 days post-infection by flow cytometry after PI staining. (B) Immu-
noblot to confirm the WNT5B knockdown and to determine the expression of cyclin E and Cyclin D1. (C) ShWNT5B induced cell apoptosis. Cells
were stained with Annexin V and PI followed by flow cytometry analysis. Bars represent the average of Annexin V or Annexin V plus PI cell num-
ber (n = 3). For Annexin V staining, P = 0.0032; for Annexin V plus PI staining, P = 0.0051. ** P < 0.01. (D) Immunoblot analysis of caspase-3 and
caspase-8 based on the marker size to determine full length and cleaved proteins.
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the other hand, with the inhibition of WNT5B, the cell
survival length seemed to be shortened. We sought to
determine whether it is caused by cellular apoptosis.
The AnnexinV staining was conducted followed by flowcy-
tometry analysis. The AnnexinV positive cell was 1.79% in
shCtl-infected MDA-MB-231 cells, whereas it increased to
8.43% in the cells with WNT5B inhibition. The total of
AnnexinV and PI positive cell was 8.30% in control cells
and it went up to 21.11% in MDA-MB-231/shWNT5B
cells. Both populations of AnnexinV positive cells and of
AnnexinV plus PI positive cells were significantly increasedwith shWNT5B expression (Figure 3c). To identify whether
the apoptosis induced by WNT5B knockdown is caspase-
dependent, we did immunoblot analysis to determine the
cleavage of Caspase 3/Caspase 8 in MDA-MB-231 cells.
Neither the cleavage of Caspase 3 nor that of Caspase 8
was detected in MDA-MB-231/shWNT5B cells (Figure 3d).
It clearly suggested that WNT5B depletion lead to a
caspase-independent apoptosis, which is a feature of mito-
chondrial dysfunction. Moreover, the cell cycle analysis sup-
ported the impaired mitochondrial function as well, which
was consistent with Dr. Finkel et al’s finding. In their exper-
iments, they noticed a G0/G1 to S transition arrest through
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boost [30]. The observation of cell cycle alteration
and caspase-independent apoptosis in MDA-MB-231/
shWNT5B cells provided us a clue for characterization
of mitochondria physiology.
Knockdown of WNT5B attenuated mitochondrial
biogenesis and oxidative phosphorylation (OXPHOS) in
MDA-MB-231 cells
The electron microscope was performed to study mito-
chondria. It was shown that mitochondrial number inA
C D
Figure 4 WNT5B modulated mitochondrial homeostasis in MDA-MB-2
shCtl. For left panel images, original magnification: x 4400, scale bars: 0.5 μ
0.2 μm; for lower right image, original magnification: x 6500, scale bar: 0.5
citrate staining. (B) Immunoblot against TOM20, cyclophilin D and WNT5B.
transduced cells. (C) Western blot of TOM20 in MDA-MB-231/shWNT5B or c
(D) Morphology change of MDA-MB-231/shWNT5B or control cells exposedMDA-MB-231/shWNT5B cells was much lower than
that in shCtl-infected cells (Figure 4a Left panel, X4400).
Moreover, the mitochondrial morphology was altered
dramatically. Most mitochondria lost the typical internal
tubular structure and severe swollen was frequent.
They were no longer forming their original roundish rod
shape; instead, multiple shapes were observed (Figure 4a).
The mitochondrial size is much larger in shWNT5B ex-
pressing cells so that we had to decrease the magnifica-
tion from X11000 to X6500 for viewing some large
mitochondria in MDA-MB-231/shWNT5B cells. On theB
31 cells. (A) Electron micrograph of cells expressing shWNT5B or
m; for upper right image, original magnification: x 11000, scale bar:
μm. It was stained with 2% uranyl acetate followed by Reynold’s lead
Diminished expression of TOM20 and cyclophilin D in shWNT5B
ontrol cells with or without the presence of 50 nM mWNT5B for 72 h.
to vehicle or 50 nM mWNT5B for 72 h.
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very little or no cristae observed in the mitochondria
(Figure 4a Right panel) with WNT5B knockdown. The
immunoblot was then carried out to verify the expres-
sion of proteins that are important for mitochondrial
biology. As a result, the mitochondrial import receptor
subunit TOM20 and the key regulator of mitochondrial
permeability transition pore Cyclophilin D were barely
detected with the inhibition of WNT5B (Figure 4b). We
questioned whether worsened mitochondrial function
could be prevented by WNT5B, we applied mouse recom-
binant WNT5B (mWNT5B) to MDA-MB-231/shWNT5B
cells as well as control cells. The down-regulation of
TOM20 in shWNT5B-transduced cells was avoided by
mWNT5B (Figure 4c). In the meantime, the notable im-
provement of cell viability and growth were observed
in mWNT5B-treated MDA-MB-231/shWNT5B cells
(Figure 4d). These results highlighted the critical role
that WNT5B played in mitochondrial physiology andA B
C D
Figure 5 shWNT5B suppressed mitochondrial biogenesis in MDA-MB-
by comparing the Cox2 gene to an intron of HBB in cells transduced wit
P = 0.0089. (B) Cellular ATP was extracted from shWNT5B- or shCtl-infect
was calculated and graphed. The mean values represent 3 independent
gene expression. CYC1 and ATP5G1 mRNA was detected and normalized
experiments and 3 wells for each sample at each time point. **P = 0.009
and normalized by the cell number after oligomycin, FCCP and Rotenon
the mean ± SD. P = 0.036. *P < 0.05; **P < 0.01.implied that sufficient WNT5B was required for cell
survival in MDA-MB-231 cells. We speculated that
shWNT5B-triggered attenuation of cell viability and
growth might be caused by compromised mitochon-
drial function in each cell. The mitochondrial dysfunc-
tion for an individual cell might be resulted from the
reduction of mitochondrial number or dysfunction of
each mitochondrion inside the cells; we conducted ex-
periments to distinguish the conditions. We examined
MtDNA by qPCR in MDA-MB-231/shWNT5B and
control cells to evaluate the mitochondrial biogenesis
first. Quantitative analysis uncovered that MDA-MB-
231/shWNT5B cells showed a nearly twofold reduc-
tion in mitochondrial biogenesis compared to control
cells (Figure 5a). Most of the cellular ATP is produced
in the mitochondria; we detected the ATP level in
MDA-MB-231 cells with or without WNT5B. The ATP
generated by MDA-MB-231/shWNT5B cells was




























* * * *
231 cells. (A) qPCR analysis of mtDNA content. mtDNA was quantified
h shWNT5B or shCtl virus. Bars represent the mean ± SD (n = 3),
ed cells right before the assay, and the average single cell ATP level
experiments. P = 0.0072. (C) RT-qPCR analysis of OXPHOS-related
with GAPDH. The results represent the mean of 3 independent
1 for CYC1 and P = 0.0084 for ATP5G1. (D) The OCR was measured
e were sequentially added to the cells. The values were plotted as
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ylation, we further evaluated the expression of key
mitochondrial OXPHOS genes, such as Cytochrome
c 1 (CYC1) and ATP synthase γ subunit (ATP5G1).
Consistent with the ATP level, the notable reduction
of OXPHOS genes was observed in MDA-MB-231/
shWNT5B cells (Figure 5c). Given that mitochondrial
respiration is tightly coupled to the synthesis of ATP under
normal biological conditions, we examined whether cellular
oxygen consumption rate (OCR) altered as well. Significant
reduction of basal OCR was seen in MDA-MB-231/
shWNT5B cells compared to the control cells. However,
there seemed to be no significant difference of reserve
capacities. Interestingly, the offset difference after feeding
oligomycin was very similar to that of adding rotenone,
which suggested that there was no difference in proton
leak. Rather, it was most likely due to the less response of
mitochondria to the stimulations (Figure 5d). Given that
the attenuation of mitochondrial biogenesis had been
confirmed, it raised the possibility that the decreased mito-
chondrial mass rendered to compromised mitochondrial
function in each cell. Collectively, the data implied that
once WNT5B was down-regulated in MDA-MB-231
cells, the cells underwent cell cycle arrest and caspase-
independent death caused by decreased mitochondrial
mass. These data suggested that WNT5B was essential
for mitochondrial physiology and thus critical for cell
survival in TNBC.
Possible mechanism for shWNT5B-induced suppresion of
mitochondrial physiology
To answer if WNT5B-mediated mitochondrial biogen-
esis controlled by WNT/β-catenin pathway, we carried
out TCF promoter activity by dual luciferase assay. The
result indicated that the promoter activity of TCF de-
clined more than 50% in WNT5B inhibited cells relative
to shCtl cells; while it enhanced approximately 30% in
mWNT5B-treated MDA-MB-231 cells compared to cells
treated with vehicle control (Figure 6a). Once WNT/β-
catenin pathway was identified as a pathway that was
triggered by WNT5B, we performed correlation study of
WNT5B-related WNT/β-catenin pathway target genes
in 884 breast tumor samples; Myc was demonstrated a
significant correlation with WNT5B (Additional file 1:
Figure S4a). We further conducted genome wide survey
of WNT5B-related genes in the same sample set and
MCL1 was listed as the candidate that is positively cor-
relative with WNT5B expression (Additional file 1: Figure
S4b). Since MCL1 was an anti-apoptotic protein, which
was lately identified as the key regulator of mitochondrial
function [31]. Therefore, we hypothesized that WNT5B
might govern mitochondrial biogenesis via MCL1 that was
modulated by WNT/β-catenin target gene, Myc. In order
to determine the correlation of Myc with MCL1, IHCstaining of Myc and MCL1 was performed in 142 breast
tumor tissue array samples and the staining was graded as
weak positive (G I), medium positive (G II) and strong posi-
tive (G III). The correlative analysis of the staining revealed
that the staining grade of the two proteins was consistent
in 98 out of 142 tumor tissues, which represented a signifi-
cant correlation (Figure 6b, Additional file 1: Table S3).
These clinical data provided strong evidence that WNT5B
might modulate mitochondrial physiology through MCL1,
which was mediated by WNT/β-catenin pathway target
gene, Myc. To further confirm this hypothesis, we con-
ducted immunoblot and the results showed that shWNT5B
remarkably reduced the expression of Myc and MCL1 in
MDA-MB-231/shWNT5B cells relative to control cells.
We also assessed if WNT5B controlled mitochondrial
biogenesis through the other proteins known to contribute
to mitochondrial biogenesis, such as PGC-1a and AIF. As a
result, there is no expressional change of these two proteins
between MDA-MB-231/shWNT5B and control cells
(Figure 6c). We next verified whether Myc regulated
the expression of MCL1 in MDA-MB-231 cells. We di-
minished the expression of Myc by SiRNA targeting
Myc. As illustrated in Figure 6d, MCL1 level attenu-
ated with the suppression of Myc. This was in accord-
ance with recent report, in which Myc was recognized
as a gene that could direct transcription of MCL1 [32],
Moreover, inhibition of Myc decreased the expression
of mitochondrial structural protein, TOM20 as well
(Figure 6d). Finally, we overexpressed MCL1 in MDA-
MB-231/shWNT5B cells to evaluate if the impaired
TOM20 expression could be prevented by MCL1. As a
result, the suppressed TOM20 was brought to the level
of control cells after MCL1 was forcedly overexpressed
(Figure 6e). Taken together, the data implied that WNT5B
triggered WNT/β-catenin signaling to maintain mitochon-
drial mass and function through Myc-induced MCL1
expression.
Clinical significance of WNT5B in metastasis and disease-
free survival of TNBC
WNT5B was upregulated in TNBC and TNBC derived cell
lines. Experimental data demonstrated its critical role in
TNBC cell, MDA-MB-231. We then asked the clinical sig-
nificance of WNT5B in TNBC patients. Again, we con-
ducted large scale analysis using public domain microarray
data (Additional file 1: Table S2) to evaluate if WNT5B ex-
pression was associated with metastasis and survival. Be-
cause of the small sample size of TNBC in each cohort and
the limited availability of certain metadata for comparing
metastatic vs. non-metastatic expression or disease-free
survival within TNBC patients. Therefore, we extended the
analysis to the entire breast cancer population in the studies
that the detailed metastasis and survival information was





Figure 6 Wnt5B initiated WNT/β-catenin to govern mitochondrial biogenesis through MCL1. (A) Dual luciferase assay of TCF promoter
activity. Twenty thousand cells were seeded into 12-well plates, and the cells were transduced with shCtl or shWNT5B lenti-particles and treated
with vehicle control or 50 nM mWNT5B. The plasmid Topflash and Renilla luciferase were co-transfected into MDA-MB-231 cells at 24 h using
lipofectamine 2000. The cells were harvested for the dual luciferase assay at 48 h. Bars represent the average luciferase activities normalized to
internal control (n = 3). **P < 0.01; ***p < 0.001. (B) IHC staining of Myc and MCL1 in tissue array samples. FFPE tissue array slides were stained with
Myc or MCL1 antibody, and the staining was graded into three different levels. Nuclear staining of Myc and cytosolic staining of MCL1 were
observed. (C) Western blot of proteins related to mitochondrial structure and function. MDA-MB-231/shWNT5B and control cells were collected
for cell lysates. The protein expression of MCL-1, AIF and PGC-1α was evaluated. (D) Western blot of Myc-regulated genes. MCL1 protein was
inhibited with Myc knockdown by Myc siRNA; mitochondrial structural protein TOM20 also decreased. (E) MCL1 induced proteins in MDA-MB-231/
shWNT5B cells. TOM20 was upregulated by MCL1 independent of WNT5B expression status.
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sion of WNT5B (Figure 7a and Additional file 1: Figure
S5). With this in vivo data strongly supported our in vitro
findings; we sought to study whether WNT5B is ultimately
associated with survival. The data demonstrated that the
group with abundant WNT5B was related to lower disease-free survival rate compared to patients with lower WNT5B
level in each study. The combination of the two cohorts
achieved even better significance in the correlation of
WNT5B with disease-free survival (Figure 7b Additional
file 1: Figure S6). Similar analysis of MCL1 in the study of
Desmedt et al. yielded better significance. It might be
Yang et al. BMC Cancer 2014, 14:124 Page 11 of 13
http://www.biomedcentral.com/1471-2407/14/124because of the higher specificity of MCL1 by comparing
with its upstream gene, WNT5B. Collectively, both the
in vitro and in vivo results suggested that WNT5B-initiated
MCL1 signaling dominantly controlled the overall outcome
of breast cancer patients, especially in TNBC.
Discussion
We have previously reported that aberrant activation of
WNT signaling contributed to proliferation and metasta-
sis in TNBC cells and in animal model [11]. To carefully
address the wider role of WNT signaling playing in the
TNBC, we extended the study population from the data
in our institute to the public arrays. Firstly, WNT5B was
identified as the possible ligand for activation of WNT
signaling in TNBC. In the functional study, we found
that WNT5B played a crucial role for TNBC cells. It
empowered cell growth through regulation of the cellu-
lar energy plant, mitochondria. Most importantly, this
delicate regulation by WNT5B didn’t limited in a par-
ticular cell model; it was fundamentally associated withA
C
Figure 7 Clinical correlation of WNT5B with metastasis and disease-fr
and non-metastasis (M0) groups using TCGA microarray data. P = 0.0221 (B
groups using the combined data pulled out from the studies by Desmedt
(C) Differential expression of MCL1 in metastasis (M1) and non-metastatsis
survival analysis in the high MCL1 and low MCL1 groups using same micropatients’ metastasis and disease-free survival in a larger
population with breast cancer. These strong evidences
highlighted the promising effect that WNT5B exerts on
TNBC.
The WNT effect is highly dynamic and tissue context-
specific in human cancers. For instance, the elevated
WNT3A promotes the growth of myeloma cells in vitro
[33] and prostate tumor in mouse model [34], while it
dramatically decreases the growth of melanoma cells
transplanted in the mice [35]. Most likely, each WNT
exhibits unique sensitivities and the response upon a
particular tissue-derived cancer, which might be true for
WNT5B in TNBC. Recently, it has been noted that WNT
signal promoted mitochondrial biogenesis in mouse skeletal
myoblasts [36]; it was also observed that mitochondrial
function and oxidative phosphorylation were impaired in
hepatocytes of β-catenin knockout mice [37]; and the adi-
pocyte mitochondrial metabolism was suppressed through
WNT inhibition [19]. Collectively, we speculate that con-
vergence on the mitochondria might be a mechanism ofB
D
ee survival. (A) Differential expression of WNT5B in metastasis (M1)
) Disease-free survival analysis in the high WNT5B and low WNT5B
et al. and Wang et al. Probe, WNT5B_221029_s_at, n = 198, P = 0.0212.
(M0) groups using microarray data of Desmedt et al. (D) Disease-free
array data collected from the study of Desmedt et al.
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Despite the multitude of reports, the mechanism of how
WNT modulate mitochondrial physiology in TNBC re-
mains unexplored. In the current study, MCL1 was verified
as the responsive protein which opposed cell death through
controlling mitochondrial homeostasis. Among the Bcl-2
pro-survival protein family members, MCL1 was the one
that raised particular attention because of its high expres-
sion in extensive cancer subtypes and its functions that ex-
tended beyond apoptosis regulation, but contributed to
diverse biological process, such as malignancy and autoph-
agy [38,39]. Increased MCL1 levels in cancer cells can result
from elevated transcription or translation and decelerated
degradation [40,41]. A genome-wide study of somatic copy
number amplification (SCNA) uncovered that MCL1 was
enriched in over 3000 tumor samples collected from 26
histological types. The increased copy number of MCL1
was found in more than 10% of cancers, but the amplifica-
tion was higher in lung and breast cancers [42]. Recent re-
search progression of TNBC indicated that Myc and MCL1
are both upregulated in TNBC and they play important role
in cell survival [43]. In the current study, we demonstrated
that WNT5B-stimulated WNT/β-catenin signaling held
MCL1 at high level via its target protein, Myc. It was also
reported that GSK3 controlled MCL1 degradation by phos-
phorylation of MCL1 for ubiquitylation-dependent deg-
radation. Impaired phosphorylation of GSKs induced by
activation of WNT/β-catenin might corporate with Myc
to stabilize MCL1 in TNBC. We will address it in the fu-
ture. Taken together, our study provided wider insight
into the deeper role of WNT5B-triggered WNT/β-catenin
signaling; it might regulate breast tumor progression and
outcome by modulating mitochondrial physiology through
MCL1.
Conclusions
Taken together, the data suggest that WNT5B plays an im-
portant role in aberrant activation of WNT canonical path-
way in TNBC. Inhibition of WNT5B induces cell cycle
arrest and caspase-independent apoptosis, which is caused
by attenuated mitochondrial biogenesis. WNT5B modu-
lates mitochondrial biogenesis through MCL1, which is
regulated by WNT/β-catenin responsive gene, Myc. These
findings provide promising evidences to target WNT5B-
indeced WNT/β-catenin signaling in TNBC.
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